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A B S T R A C T 
Objectives: To examine the molecular pathogenetic 
mechanisms, (epi)genotype-phenotype correlation, 
and the performance of the three clinical scoring 
systems—namely Netchine et al, Bartholdi et al, and 
Birmingham scores—for patients with Silver-Russell 
syndrome in Hong Kong. 
Methods: This retrospective case series was 
conducted at two tertiary genetic clinics, the Clinical 
Genetic Service, Department of Health, and clinical 
genetic clinic in Queen Mary Hospital in Hong 
Kong. All records of patients with suspected Silver-
Russell syndrome under the care of the two genetic 
clinics between January 2010 and September 2015 
were retrieved from the computer database. 
Results: Of the 28 live-birth patients with Silver-
Russell syndrome, 35.7% had H19 loss of DNA 
methylation, 21.4% had maternal uniparental 
disomy of chromosome 7, 3.6% had mosaic maternal 
uniparental disomy of chromosome 11, and the 
remaining 39.3% were Silver-Russell syndrome 
of unexplained molecular origin. No significant 
correlation between (epi)genotype and phenotype 
could be identified between H19 loss of DNA 
methylation and maternal uniparental disomy 
of chromosome 7. Comparison of molecularly 
confirmed patients and patients with Silver-Russell 
syndrome of unexplained origin revealed that 
Silver-Russell syndrome in Hong Kong
Introduction
Silver-Russell syndrome (SRS) [OMIM 180860] is a 
clinically and genetically heterogeneous congenital 
imprinting disorder. It was first described in 1953 
by Dr Henry Silver and his colleagues, who reported 
two children with short stature and congenital 
hemihypertrophy.1 In the following year, Dr 
Alexander Russell reported five similar cases with 
intrauterine dwarfism and craniofacial dysostosis.2 
The term SRS has been used since 1970 to describe 
a constellation of features with intrauterine growth 
retardation without postnatal catch-up, distinct 
facial characteristics, relative macrocephaly, body 
New knowledge added by this study
• The epigenetic defects of Silver-Russell syndrome (SRS) in Hong Kong Chinese patients are comparable to those 
reported in western populations.
• No epigenotype-phenotype correlation was demonstrated among SRS patients in this study.  
Implications for clinical practice or policy
• All suspected SRS patients should be referred to a genetic clinic for assessment.
• A new diagnostic algorithm has been proposed for Chinese patients with SRS.
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asymmetry, and/or fifth finger clinodactyly.3,4 The 
prevalence of SRS was estimated to be 1 in 100 000,5 
but was probably underestimated due to the diverse 
and variable clinical manifestations. The majority of 
SRS cases are sporadic, although occasional familial 
cases have been reported. 
 Two major molecular mechanisms have been 
implicated in SRS—maternal uniparental disomy 
of chromosome 7 (mUPD7)6 and loss of DNA 
methylation (LOM) of the imprinting control region 
1 (ICR1) on the paternal allele of chromosome 
11p15 region that regulates the IGF2/H19 locus.6-9 
According to the studies, LOM of ICR1 and 
ORIGINAL ARTICLE
postnatal microcephaly and café-au-lait spots were 
more common in the latter group, and body and limb 
asymmetry was more common in the former group. 
Performance analysis showed the Netchine et al and 
Birmingham scoring systems had similar sensitivity 
in identifying Hong Kong Chinese subjects with 
Silver-Russell syndrome. 
Conclusion: This is the first territory-wide study of 
Silver-Russell syndrome in Hong Kong. The clinical 
features and the spectrum of underlying epigenetic 
defects were comparable to those reported in 
western populations.
#  Silver-Russell syndrome  # 
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香港的Silver-Russell綜合症
陸浩明、楊傑燊、王偉立、鍾侃言、唐鳴科、盧輝文
目的：研究香港Silver-Russell綜合症（SRS）患者的分子發病機制
以及表觀基因型和臨床表現型的關連性，並檢視三個臨床評分系統
（Netchine等、Bartholdi等，以及Birmingham評分標準）的應用。
方法：本回顧性病例系列研究於香港瑪麗醫院和衛生署醫學遺傳服務
中心的遺傳輔導診所內進行。從電腦紀錄中找出2010年1月至2015年
9月期間被轉介到以上兩所遺傳輔導診所的疑似SRS患者的數據。
結果：在本研究的28名SRS患者中，分子遺傳化驗結果發現35.7%
為H19甲基化損失（LOM）、21.4%為7號染色體母源單親二體症
（mUPD7）、3.6%為鑲嵌11號染色體母源單親二體症（mUPD11），
餘下的39.3%則屬原因不明。LOM與mUPD7在表觀基因型和臨床表
現型之間無顯著相關。然而，比較分子確認患者和原因不明的患者，
前者有較多頭和身體不對稱，後者的頭圍較細和咖啡牛奶斑則較為常
見。三個臨床評分系統分析顯示Netchine以及Birmingham評分標準在
檢測香港SRS華籍患者的敏感度相若。
結論：這是香港首項針對SRS的全港性臨床研究。結果顯示香港SRS
患者的臨床特點和表觀遺傳缺陷的頻譜與西方人群相若。
mUPD7 roughly account for 45% to 50% and 5% to 
10% of SRS cases, respectively.6-9 Rare cytogenetic 
rearrangements have also been reported in 1% to 2% 
of cases.4,10,11 There remain 30% to 40% of SRS cases 
in which the molecular mechanisms remain elusive, 
however. 
 Owing to the wide spectrum of clinical 
presentations of SRS, there is considerable clinical 
overlap with other growth retardation syndromes. 
At present there is no consensus for the diagnostic 
criteria, so diagnosing SRS is challenging. Several 
scoring systems have been proposed to facilitate 
clinical diagnosis and to guide genetic testing.7,11-14 
Based on the prevalence of different molecular 
mechanisms, methylation study of the 11p15 region 
is the recommended first-tier investigation for 
patients with suspected SRS, and mUPD7 analysis is 
the second tier.14 
 The comprehensive clinical spectrum and 
molecular study of SRS have not been reported in 
the Chinese population. Therefore, a retrospective 
review that aimed to summarise the clinical and 
genetic findings of all SRS patients in Hong Kong 
was conducted. The sensitivity and specificity of 
different scoring systems7,11-14 in identifying Hong 
Kong Chinese SRS patients have also been studied.
Methods
Patients
The Clinical Genetic Service (CGS), Department of 
Health and the clinical genetic clinic at Queen Mary 
Hospital (QMH), The University of Hong Kong, are 
the only two tertiary genetic referral centres that 
provide comprehensive genetic counselling, and 
diagnostic and laboratory service for the Hong Kong 
population. Patients with a clinical suspicion of 
growth failure due to genetic causes or possibly SRS 
were referred for assessment and genetic testing. 
 In this review, all records of patients 
with suspected SRS seen at the CGS or clinical 
genetic clinic of QMH between January 2010 and 
September 2015 were retrieved from the computer 
database system using the key words of “Silver 
Russell syndrome” and “failure to thrive and growth 
retardation”. The clinical and laboratory data of these 
patients were retrospectively analysed. Patients with 
alternative diagnoses after assessment and genetic 
investigation were excluded. This study was done 
in accordance with the principles outlined in the 
Declaration of Helsinki.
Clinical diagnostic criteria for Silver-Russell 
syndrome in this study
Currently, there is no universal consensus on the 
diagnostic criteria of SRS, but the Hitchins et al’s 
criteria15 are the most commonly used clinically. 
The diagnosis of SRS in this study was made when 
a patient fulfilled three major, or two major and two 
minor criteria. 
 Major criteria included (1) intrauterine 
growth retardation/small for gestational age (<10th 
percentile); (2) postnatal growth with height/length 
<3rd percentile; (3) normal head circumference 
(3rd-97th percentile); and (4) limb, body, and/or 
facial asymmetry.
 Minor criteria included (1) short arm span 
with normal upper-to-lower segment ratio; (2) fifth 
finger clinodactyly; (3) triangular facies; and (4) 
frontal bossing/prominent forehead.
Epimutation in imprinting control region 1 
Investigation of the methylation status and copy 
number change of the H19 differentially methylated 
region (H19 DMR) and KvDMR1 at chromosome 
11p15 region was done with methylation specific–
multiplex ligation-dependent probe amplification 
(MS-MLPA) method, using SALSA MLPA ME030-
B1 BWS/RSS kit (MRC-Holland, Amsterdam, 
The Netherlands). Following the manufacturer’s 
instructions, approximately 100 ng genomic DNA 
was first denatured and hybridised overnight with 
the probe mixture supplied with the kit. The samples 
were then split into two portions, treated either with 
ligase alone or with ligase and HhaI. Polymerase 
chain reactions (PCR) were then performed with the 
reagents and primers supplied in the kit. The PCR 
products were separated by capillary electrophoresis 
(model 3130xl; Applied Biosystems, Foster City 
[CA], US). The electropherograms were analysed 
using GeneScan software (Applied Biosystems, 
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Foster City [CA], US), and the relative peak area was 
calculated using the Coffalyser version 9.4 software 
(MRC-Holland, Amsterdam, The Netherlands).
Analysis of maternal uniparental disomy of 
chromosome 7
We studied mUPD7 with eight polymorphic 
microsatellite markers, three on 7p and five on 7q 
(D7S531, D7S507, D7S2552, D7S2429, D7S2504, 
D7S500, D7S2442, and D7S2465), using a standard 
protocol. Haplotype analysis was then performed. A 
diagnosis of mUPD7 required evidence of exclusive 
maternal inheritance at two or more informative 
markers.
Data analysis and (epi)genotype-phenotype 
correlation
Epidemiological data, physical characteristics, 
growth records, and molecular findings were 
then collected for analysis. Clinical photographs 
were taken during consultation (Fig 1). In order to 
delineate the (epi)genotype-phenotype correlation, 
we divided the patients according to their 
(epi)genotype, namely H19 LOM, mUPD7, mosaic 
maternal uniparental disomy of chromosome 11 
(mUPD11), or SRS of unexplained origin. The SRS of 
unexplained origin was defined as negative for 11p15 
region epimutation and mUPD7 study. For statistical 
calculation, Student’s t test was used for continuous 
FIG 1.  Clinical photos for molecularly confirmed SRS in this study
Patients with (a to d) mUPD7 and (e to g) H19 LOM. All had relative macrocephaly, frontal bossing, triangular face, and pointed chin. 
Patients showing (e) fifth finger clinodactyly and (f) body asymmetry. (h) Informative microsatellite markers in UPD study that shows 
mUPD7
Abbreviations: LOM = loss of DNA methylation; mUPD7 = maternal uniparental disomy of chromosome 7; SRS = Silver-Russell 
syndrome; UPD = uniparental disomy
(a)
(e) (f) (g) (h)
(b) (c)
(d)
#  Silver-Russell syndrome  # 
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variables and Fisher’s exact test for categorical 
variables. Two-tailed P values were also computed. 
Differences were considered to be statistically 
significant when P≤0.05.
Clinical score
Three clinical scoring systems were applied to all 
patients referred with suspected SRS and included 
Netchine et al score,7 Bartholdi et al score,12 and the 
Birmingham score.14 An overview of the three SRS 
scoring systems is summarised in Table 1. Using the 
Hitchins et al’s criteria15 as standard in this study, 
the sensitivity and specificity of these three scoring 
systems in identifying SRS were compared. 
Results
During the study period, 83 patients with suspected 
SRS were referred to both genetic clinics. After 
clinical assessment and investigations, 54 patients 
had an alternative diagnosis. The remaining 29 
patients were clinically diagnosed with SRS using 
the Hitchins et al’s criteria.15 All were Chinese. One 
was a prenatal case with maternal H19 duplication. 
Since termination of pregnancy was performed at 23 
weeks of gestation, it was excluded for downstream 
analysis. For the remaining 28 SRS patients, their 
age at the end of the study (September 2015) ranged 
from 2 years to 22 years 9 months, with a median 
of 9 years 4 months. The male-to-female ratio was 
9:5. Sequential MS-MLPA study on chromosome 
11p15 region and mUPD7 study were performed 
on all SRS patients. Among the 28 live-birth SRS 
patients, 35.7% (n=10) had H19 LOM, 21.4% (n=6) 
had mUPD7, 3.6% (n=1) had mosaic mUPD11, and 
39.3% (n=11) were of SRS of unexplained origin. The 
clinical features of the SRS cohort are summarised 
in Table 2. The clinical features of some molecularly 
confirmed SRS patients in this study and one 
illustrative microsatellite electropherogram in 
mUPD7 analysis are shown in Figure 1. 
 In order to study the (epi)genotype-phenotype 
correlation among the H19 LOM and mUPD7 
groups, the clinical features were compared. 
There was no significant difference among the 
two groups (data not shown). When comparing 
the 28 molecularly confirmed SRS and 54 SRS of 
unexplained origin patients, postnatal microcephaly 
(P=0.01) and café-au-lait spots (P=0.05) were more 
common among SRS of unexplained origin, while 
body asymmetry (P<0.01) and limb asymmetry 
(P<0.01) were more common among the molecularly 
confirmed group. 
 The performance of the three clinical scoring 
systems namely Netchine et al score,7 Bartholdi et 
al score,12 and Birmingham score14 in identifying 
SRS in our cohort was compared. The proportion 
of molecularly confirmed cases in those ‘likely SRS’ 
and ‘unlikely SRS’ based on the scoring system are 
summarised in Table 3. The sensitivity and specificity 
among different scoring systems for identifying SRS 
are summarised in Table 4. 
TABLE 1.  Comparison of three common clinical scoring systems for SRS
Netchine et al score7 Bartholdi et al score12 Birmingham score14
Requirement for 
‘likely SRS’ 
Mandatory + 5-factor system (3 of 5 positive) 15-Factor system (≥8 positive) 4-Factor system (≥3 positive)
Details Mandatory: SGA birth weight and/or  
length ≤ –2 SD
(1) Postnatal growth ≤ –2 SD at 24 months
(2) Relative macrocephaly at birth*
(3) Body asymmetry‡
(4) Feeding difficulties§ and/or low BMI  
(BMI ≤ –2 SD at 24 months)
(5) Protruding forehead as a toddler
Growth parameters
(1) Birth weight ≤10th percentile
(2) Birth length ≤10th percentile
(3) Relative macrocephaly at birth*
(4) No catch-up growth, height ≤3rd percentile
(5) OFD ≥3rd percentile and ≤97th percentile
Facial dysmorphism
(6) Triangular-shaped face
(7) Prominent forehead
(8) Small chin or thin lips or delayed closure of 
fontanelle
Somatic features and intellectual function 
(9-11) Physical asymmetry (face/limb/body)
(12) Attending regular school
(13) Fifth digit clinodactyly
(14) Genital abnormalities
(15) Others (eg pigmentary anomalies)
(1) SGA birth weight ≤2 SD
(2) Postnatal growth ≤2 SD any 
time after 2 years
(3) Relative macrocephaly†
(4) Body asymmetry
Abbreviations: BMI = body mass index; OFD = occipitofrontal diameter; SD = standard deviations; SGA = small for gestational age; SRS = Silver-Russell 
syndrome
* Head circumference SD ≥1.5 SD higher than birth weight or length
† Head circumference SD ≥1.5 SD higher than weight or length at the time of measurement 
‡ Leg length discrepancy (LLD) of ≥0.5 cm or arm asymmetry or LLD <0.5 cm with at least two other asymmetric body parts (one not relating to the 
face) 
§ Use of a feeding tube or use of appetite stimulation for a child with a very low spontaneous food intake
  #  Luk et al #
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Discussion 
Silver-Russell syndrome is a clinically and 
genetically heterogeneous disorder. This is the first 
comprehensive clinical and epigenetic study of SRS 
in Hong Kong. With sequential 11p15 epimutation 
analysis and mUPD7 study of SRS patients in this 
cohort, molecular confirmation was achieved in 
60.7% of cases; H19 LOM and mUPD7 accounted for 
35.7% and 21.4% of the cases, respectively. Although 
the proportion of H19 LOM–related SRS cases was 
similar to the western and Japanese populations,6-9,16 
the proportion of mUPD7 in our cohort was 
significantly higher. Nonetheless, due to the small 
sample size, this observation might not reflect the 
true ethnic-specific epigenetic alteration in the 
Chinese population. Further studies are necessary to 
confirm this difference. 
 In previous studies of (epi)genotype-phenotype 
correlation4,7,12,17-20 in SRS, patients with mUPD7 
had a milder phenotype but were more likely to 
have developmental delay. On the contrary, patients 
with H19 LOM appeared to have more typical SRS 
features such as characteristic facial profile and 
body asymmetry. Such a correlation could not be 
demonstrated in our cohort. When comparing the 
molecularly confirmed and SRS of unexplained 
origin groups, postnatal microcephaly and café-au- 
lait spots were more common in the group of SRS of 
unexplained origin, while body/limb asymmetry was 
more common in the molecularly confirmed group. 
This observation has also been reported in Japanese 
SRS patients.16 This might be due to the greater 
clinical and genetic heterogeneity in the molecularly 
negative SRS.
 Although SRS has been extensively studied, 
there remains no universal consensus on the clinical 
diagnostic criteria. Hitchins et al’s criteria15 are 
currently the most commonly used. In order to 
facilitate the clinical diagnosis, several additional 
scoring systems have been proposed which include 
the Netchine et al,7 Bartholdi et al,12 and Birmingham 
scores.14 Each of them has its advantages and 
limitations. The major caveats of those scoring 
systems include relative subjectivity of clinical 
signs, and time-dependent and evolving clinical 
features. The heterogeneity of clinical manifestations 
also limits their application. In order to validate 
these scoring systems, several studies have been 
performed to evaluate their accuracy in predicting 
the molecular genetic testing result.14,21 We also 
evaluated the performance of these three scoring 
TABLE 2.  Summary of the clinical features in different subgroups of SRS patients
Clinical feature H19 LOM (n=10) mUPD7 (n=6) Mosaic mUPD11 
(n=1)
SRS of unexplained 
origin (n=11)
Prematurity 2 3 1 1
Small for gestational age 10 6 1 11
Relative macrocephaly 5 4 0 4
Hypoglycaemia 2 0 1 2
Catch-up growth 0 1 0 0
Postnatal microcephaly 2 0 1 8
Developmental delay 1 2 1 6
Facial asymmetry 4 2 0 1
Body asymmetry 8 3 1 0
Limb asymmetry 8 3 1 0
Triangular face 9 5 1 11
Frontal bossing 9 6 1 10
Micro/retrognathia 1 2 0 5
Downturned corners of the mouth 3 2 0 1
Fifth finger clinodactyly 7 3 1 5
Genital abnormality 0 0 1 1
Café-au-lait spot 0 1 0 4
Blue sclera 2 1 0 1
Congenital heart disease 1 0 1 1
Skeletal deformity 2 2 1 0
Growth hormone treatment 1 2 0 0
Abbreviations: LOM = loss of DNA methylation ; mUPD7 = maternal uniparental disomy of chromosome 7; SRS = Silver-Russell 
syndrome
#  Silver-Russell syndrome  # 
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systems in this Chinese cohort. All three scoring 
systems are 100% specific in diagnosing SRS, but the 
sensitivity for Netchine et al score,7 Bartholdi et al 
score,12 and Birmingham score14 is 75%, 53.6%, and 
71.4%, respectively when compared with Hitchins 
et al’s criteria.15 This suggests that Hitchins et al’s 
criteria15 remain the most sensitive diagnostic 
criteria for SRS when used clinically. 
 The management of SRS is challenging and 
requires multidisciplinary input. Growth hormone 
(GH) treatment is the current recommended therapy 
for children with small for gestational age without 
spontaneous catch-up growth and those with GH 
deficiency. In SRS, abnormalities in spontaneous GH 
secretion and subnormal responses to provocative 
GH stimulation have been well reported.20 The 
proposed mechanism is dysregulation of the growth 
factors and its major binding protein,4 particularly 
in the H19 LOM group. Besides, SRS patients are 
expected to have poor catch-up growth. Nonetheless, 
GH therapy is not a universal standard treatment for 
SRS. In Hong Kong, the indications for GH therapy 
under Hospital Authority guidelines do not include 
SRS22 without GH response abnormalities. In our 
cohort, only three patients who had a suboptimal 
GH provocative stimulation test are currently 
receiving GH treatment. The long-term outcome is 
not yet known. 
 Although tissue-specific epigenetic 
manifestation has been reported in SRS,23 mosaic 
genetic or epigenetic alteration is uncommon.24 
We have one patient with mUPD11 confirmed by 
molecular testing with peripheral blood and buccal 
swab samples. Mosaicism should be considered 
when a patient has typical SRS phenotype but 
negative routine testing. Testing of other tissue 
should be pursued so as to provide an accurate 
molecular diagnosis that can guide subsequent 
genetic counselling and clinical management.
 Finally, upon review of the literature, it is well 
known that gain of function of the CDKN1C gene25 
and maternal UPD14 (Temple syndrome)26,27 can 
result in a phenotype mimicking SRS. There are also 
other syndromic growth retardation disorders with 
many overlapping clinical features with those of SRS, 
such as mulibrey nanism and 3-M syndrome.28,29 
Therefore, with the latest understanding of the 
molecular pathogenetic mechanisms of SRS, 
together with evidence21,30,31 and results from this 
study, we propose the diagnostic algorithm for 
TABLE 3.  Proportion of different SRS subtypes with ‘likely SRS’ and ‘unlikely SRS’ score in different scoring systems in our cohort
Scoring system Requirement for ‘likely SRS’ H19 LOM (n=10) mUPD7 (n=6) Mosaic mUPD11  
(n=1)
SRS of unexplained 
origin (n=11)
Netchine et al score7 ≥3 Factors 100% 100% 100% 36.4%
Bartholdi et al score12 ≥8 Factors 80.0% 83.3% 100% 9.1%
Birmingham score15 ≥3 Factors 90.0% 100% 100% 36.4%
Requirement for ‘unlikely SRS’
Netchine et al score7 ≤2 Factors 0 0 0 63.6%
Bartholdi et al score12 ≤7 Factors 20.0% 16.7% 0 90.9%
Birmingham score15 ≤2 Factors 10.0% 0 0 63.6%
Abbreviations: LOM = loss of DNA methylation ; mUPD7 = maternal uniparental disomy of chromosome 7; SRS = Silver-Russell syndrome
Abbreviations: CI = confidence interval; NA =  not applicable; SRS = Silver-Russell syndrome
* All 95% CIs of specificity in these 3 scores are 1
TABLE 4.  The sensitivity and specificity of the three clinical scoring systems compared with Hitchin et al’s criteria15 in identifying SRS in our cohort
Netchine et al score7 Bartholdi et al score12 Birmingham score14
‘Likely SRS’ ‘Unlikely SRS’ ‘Likely SRS’ ‘Unlikely SRS’ ‘Likely SRS’ ‘Unlikely SRS’
Hitchin et al’s criteria15
Clinically SRS 21 7 15 13 20 8
Clinically not SRS 0 54 0 54 0 54
Sensitivity 75.0% (21/28) 53.6% (15/28) 71.4% (20/28)
95% CI 74.5-75.5% 53.0-54.2% 70.9-72.0%
Specificity 100% (54/54) 100% (54/54) 100% (54/54)
95% CI* NA NA NA
  #  Luk et al #
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Chinese SRS patients as depicted in Figure 2. All 
clinically suspected SRS patients should be assessed 
by a clinical geneticist. Although the Netchine et 
al score,7 Bartholdi et al score,12 and Birmingham 
score14 are highly specific, they are less sensitive than 
the Hitchins et al’s criteria15 for diagnosing SRS in 
our Chinese cohort. Therefore, the Hitchins et al’s 
criteria15 should be used clinically to classify those 
suspected SRS patients into ‘likely’ or ‘unlikely’ SRS. 
For those ‘likely SRS’ patients, sequential 11p15 
region methylation study and mUPD7 analysis should 
be performed because 11p15 region epigenetic 
alteration is more prevalent than mUPD7 in SRS. For 
those molecularly unconfirmed SRS, further testing 
for other SRS-like syndromes including Temple 
syndrome or CDKN1C-related disorder should be 
pursued if indicated. 
Conclusion
This 5-year review is the first territory-wide study 
of Chinese SRS patients in Hong Kong. It showed 
that the clinical features and underlying epigenetic 
mechanisms of Chinese SRS are similar to those 
of other western populations. Early diagnosis and 
multidisciplinary management are important for 
managing SRS patients. Vigilant clinical suspicion 
with confirmation by molecular testing is essential. 
Based on the current evidence and performance 
evaluation of different clinical scoring systems, a 
comprehensive diagnostic algorithm is proposed. We 
hope that with an increase in understanding of the 
underlying pathophysiology and the (epi)genotype-
phenotype correlation in Chinese SRS patients, the 
quality of medical care will be greatly improved in 
the near future.
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FIG 2.  Proposed algorithm for management and genetic investigations for suspected SRS in Hong Kong
Abbreviations: DMR = differentially methylated region; MS-MLPA = methylation specific–multiplex ligation-dependent probe 
amplification; mUPD7 = maternal uniparental disomy of chromosome 7; SNP = single nucleotide polymorphism; SRS = Silver-
Russell syndrome
Patients with suspected SRS features
Reviewed by clinical geneticists
Patients with ‘likely SRS’ Patients with ‘unlikely SRS’
Consider alternative diagnosis
Molecular confirmed SRS
CDKN1C gene/14q32.2  
DMR study
• Oligonucleotide array/SNP array for copy 
number change/uniparental disomy
• Targeted genetic testing for syndromal disease
• Consider alternative diagnosis
Molecular unconfirmed SRS
11p15 Epimutation study (eg 
MS-MLPA test) and/or mUPD7 analysis 
(microsatellite study)
Clinical diagnostic criteria 
(Hitchins et al’s criteria15)
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